Search the Newsreel

Pioneer Pow earnings missed by $0.09, revenue fell short of estimates

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

Levi & Korsinsky, LLP is investigating potential securities law violations involving Tenax Therapeutics (TENX) after its shares dropped 84-85%. This significant decline followed the disclosure that the Phase 3 LEVEL trial of its lead drug, TNX-103, failed to meet both its primary and key …

PDF Solutions (PDFS) Is Up 6.9% After Reaffirming 20% Growth And Filing ESOP Shelf Offering

PDF Solutions (PDFS) saw its stock rise by 6.9% after reporting its Q2 2026 results, reaffirming a 20% annual revenue growth target, and filing a US$91.80 million shelf registration for an ESOP-related share offering. This combination of profitability, growth ambitions, and capital flexibility highlights …

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Should You Buy?

Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate

Fulcrum Therapeutics, which previously cut 85% of its workforce after discontinuing its sickle cell disease program, is undergoing a reverse merger with North Carolina-based Slate Medicines. The merger is anticipated to finalize in the fourth quarter of the year. Fulcrum is currently located at …

Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE." …

What's Going On With Kratos Defense Stock Monday?

Why Medexus Pharmaceuticals Inc stock is sliding today

Revolution Medicines stock hits all-time high at 208.77 USD

Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is …

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The …

Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed

Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, had 2,714 shares of company common stock withheld to cover tax obligations stemming from the vesting of Restricted Stock Units. The shares were valued at $4.25 each. Following this transaction, Korczynski directly holds 235,689 shares of Aquestive …

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. …

Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)

PHAT Maintains Overweight Rating -- Price Target Lowered to $14

Barclays has maintained an "Overweight" rating for Phathom Pharmaceuticals (PHAT) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook despite the company being significantly undervalued according to GuruFocus's GF Value™. The company, which specializes in gastrointestinal treatments, faces financial health …

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) is up ~7% Monday following rival EyePoint's …

Emergent BioSolutions faces securities probe after $191M NARCAN impairment and $97M adjusted EBITDA report

Emergent BioSolutions is facing a securities probe by Levi & Korsinsky law firm following a reported $191.3 million non-cash impairment on its NARCAN product and a subsequent decline in its stock. The company's Q2 revenue was $234 million with $97 million in adjusted EBITDA, …

Veranda Learning Q1FY27 net profit up 471% to ₹339 crore; guides ₹670 crore revenue

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Got $200? 1 Quantum Computing ETF to Buy Right Now.

If you have $200 and want to point it at something that feels like the future, Defiance Quantum ETF (NASDAQ: QTUM) is a serious contender instead of a science project. When you buy this ETF, you're buying a basket of companies that are already …

Universal Technical Institute cuts FY2026 EBITDA outlook, shares drop sharply amid investigation.

Universal Technical Institute (UTI) has reduced its fiscal year 2026 adjusted EBITDA forecast from over $155 million to above $135 million, leading to a significant drop in its stock price. The company attributed this cut to lower-than-expected enrollment in its high-school auto and diesel …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong Q2 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increased confidence in XDEMVY's commercial trajectory supports the company's near-term revenue, though risks related to …

Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why

Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss …

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates

NRX Pharmaceuticals (NASDAQ: NRXP) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.440, significantly worse than the $-0.113 estimate, and revenue of $1.1M, falling short of the $1.75M consensus. Despite the miss, the stock …

Loss of China Rights for Jing Zhu Da Might Change The Case For Investing In Syndax (SNDX)

Why Cardiol Therapeutics Inc Class A stock is gaining today

Jacobs nabs MMSD committee backing, pledges to cut Palantir. What next?

An ad hoc committee has recommended Jacobs Solutions as the next wastewater operator for the Milwaukee Metropolitan Sewerage District (MMSD), passing over the current operator, Veolia. Jacobs secured this backing after pledging to terminate its partnership with Palantir, a controversial software company. This decision …

Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral

Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company …

Consensus Cloud Solutions (NASDAQ:CCSI) Stock Price Down 6.2% Following Insider Selling

Consensus Cloud Solutions (NASDAQ:CCSI) experienced a 6.2% stock price drop after CTO Jeffrey Alan Sullivan sold 5,400 shares, reducing his direct stake by 4.49%. Despite this insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of …

Dermata Therapeutics raises $3.4 million in private placement

Dermata Therapeutics (NASDAQ:DRMA) has announced a private placement offering expected to generate approximately $3.4 million in gross proceeds. The offering includes common stock or pre-funded warrants, along with series E and F warrants, priced at $1.46 per share. Company insiders are also participating, and …

DA Davidson reiterates PDF Solutions stock rating on eProbe growth

DA Davidson has reiterated a Buy rating and a $74.00 price target for PDF Solutions Inc. (NASDAQ:PDFS), citing strong demand for the company's eProbe tool and expectations for continued growth. The firm's analysis follows a visit to PDF Solutions' San Jose facility, where they …

Fulcrum Therapeutics stock rises on Slate Medicines merger deal

Fulcrum Therapeutics Inc (NASDAQ:FULC) shares rose after announcing a definitive agreement to merge with Slate Medicines Inc in an all-stock transaction. The combined company, to be named Slate Medicines, will focus on advancing migraine therapeutics and secured an oversubscribed private placement of $245 million …

The Quantum Race Is Heating Up—And 2 Small Players Stand Out

Quantum Computing Inc. (QUBT) and Infleqtion Inc. (INFQ), two smaller quantum technology companies, have reported strong revenue growth but are grappling with rapidly increasing operating expenses and losses. While larger player IonQ has distinguished itself with strong performance and strategic acquisitions, D-Wave Quantum fell …

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Galmed Pharmaceuticals announced preclinical study results showing that a combination of Aramchol and Xtandi® (enzalutamide) led to a 3-4 fold increase in cell death in prostate cancer models compared to Xtandi® alone. This combination targets the lipid metabolism pathway that prostate cancer cells adapt …

ORKA Q2 2026 Earnings: Wider Loss Reflects R&D Investment as Pre-Revenue Biotech Advances Pipeline - Earnings Power Value